
Senti Biosciences, Inc. — Investor Relations & Filings
Senti Biosciences, Inc. is a clinical-stage biotechnology company developing a new generation of cell and gene therapies. The company's core technology is its synthetic biology platform, which designs and optimizes proprietary "Gene Circuits." These circuits, created from novel combinations of DNA sequences, are engineered to reprogram cells with biological logic, enabling them to sense inputs, compute decisions, and respond to their cellular environments. This approach aims to create smarter medicines with enhanced therapeutic effectiveness and safety. Senti Bio is applying its Gene Circuit technology to develop a pipeline of product candidates, primarily for the treatment of cancer, designed to precisely target and eliminate malignant cells while sparing healthy tissue.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-26 | English | |
| 10-Q | 2026-05-14 | English | |
| 8-K | 2026-05-14 | English | |
| S-8 - Senti Biosciences, Inc. (0001854270) (Filer) | 2026-04-24 | English | |
| S-8 POS - Senti Biosciences, Inc. (0001854270) (Filer) | 2026-04-24 | English | |
| S-8 POS - Senti Biosciences, Inc. (0001854270) (Filer) | 2026-04-24 | English |
Browse filings by year
6 yearsMarket data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Oxurion NV
Acquires majority stakes in European pharmaceutical subcont…
|
OXUR | BE | Professional, scientific and te… |
|
PACIFIC EDGE LIMITED
Develops non-invasive molecular tests for bladder cancer de…
|
PEB | NZ | Professional, scientific and te… |
|
PARADIGM BIOPHARMACEUTICALS LIMITED..
Repurposing PPS for osteoarthritis and rare inflammatory di…
|
PAR | AU | Professional, scientific and te… |
|
Pasithea Therapeutics Corp.
Develops treatments for central nervous system disorders, R…
|
KTTA | US | Professional, scientific and te… |
|
Passage BIO, Inc.
A clinical-stage genetic medicines company developing thera…
|
PASG | US | Professional, scientific and te… |
|
PATRYS LIMITED
Develops Deoxymab antibody therapies targeting DNA repair m…
|
PAB | AU | Professional, scientific and te… |
|
PAVmed Inc.
A diversified medical technology company developing devices…
|
PAVM | US | Professional, scientific and te… |
|
PegBio Co., Ltd.
Specializes in discovering and developing innovative therap…
|
2565 | HK | Professional, scientific and te… |
|
PELL BMT
Develops advanced cell and gene therapies, including CAR-T …
|
6949 | TW | Professional, scientific and te… |
|
PepGen Inc.
Develops oligonucleotide therapeutics for neuromuscular and…
|
PEPG | US | Professional, scientific and te… |
Senti Biosciences, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34717/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34717 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34717 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34717 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34717}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Senti Biosciences, Inc. (id: 34717)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.